Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial.
Choueiri TK, Kuzel TM, Tykodi SS, Verzoni E, Kluger H, Nair S, Perets R, George S, Gurney H, Pachynski RK, Folefac E, Castonguay V, Lee CH, Vaishampayan U, Miller WH Jr, Bhagavatheeswaran P, Wang Y, Gupta S, DeSilva H, Lee CW, Escudier B, Motzer RJ.
Choueiri TK, et al. Among authors: miller wh jr.
ESMO Open. 2024 Dec;9(12):104073. doi: 10.1016/j.esmoop.2024.104073. Epub 2024 Dec 5.
ESMO Open. 2024.
PMID: 39642635
Free PMC article.
Clinical Trial.